强生公司正在以146亿美元收购Intra-Cellular Therapies,这是自2023年以来最大的生物技术并购交易,也是2024年以来首个超过100亿美元的生物医药并购。Intra-Cellular股价在盘前交易中飙升近38%,而强生公司股价持平。风险提示及免责条款 市场有风险,投资需谨慎。本文不构成个人投资建议,也未考虑到个别用户特殊的投资目标、财务状况或需要。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.